Medtronic plc announced the CE (Conformité Européenne) mark and European launch of the CoreValve Evolut R 34 mm valve — the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at intermediate, high or extreme risk for surgery with an annulus size ranging from 26-30 mm. This large valve segment is estimated to account for approximately 20-25 percent of the eligible European TAVI patient population. Previously, some of these patients were unable to receive a TAVI due to the larger size of their native diseased aortic valve.

Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac arrest or a near-fatal arrhythmia, almost 80 percent survived two years, according to a new study in the Journal of the American College of Cardiology. This is a higher rate than found in past trials performed to demonstrate the efficacy of the devices in this situation.

Lumedx Corp. recently announced that it has implemented Phase 1 of a long-term, multiphase cardiovascular information system (CVIS) project with Baylor Scott & White Health.

Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure patients who have defied the odds and showed signs of recovery from the disease. Published online in the journal Circulation, the new findings could help clinicians identify the best candidates for cardiac recovery therapies.

The new SunTech Oscar 2 24-hour ambulatory blood pressure monitoring system is now available with the True24 ABPM Patient Diary mobile app, which links to the Oscar 2 via Bluetooth. The True24 app provides a tutorial on ABPM, and prompts the patient to enter information about their activity, posture or any symptoms experienced during a physician-prescribed ABPM study. This diary information helps clinicians interpret the ambulatory blood pressure study data to make well-informed hypertension treatment decisions.

MD Buyline, James Laskaris, four medical technology innovations, very near future

James Laskaris, emerging technology analyst at MD Buyline, recently offered his perspective on new medical technology innovations that might be just months or a few years away.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent
Biotronik Orsiro stent, bioresorbable polymer DES, bioresorbable polymer metallic stent

One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers that disappear and leave behind a bare metal stent. This engineering was created to solve ongoing issues in some patients whose vessels do not tolerate the antiproliferative drug-carrying polymers well, resulting in chronic inflammation. This can lead to late-stent thrombosis and is the basis for requiring long-term dual-antiplatelet therapy (DAPT).

Frost & Sullivan has released a new report, “Vision 2025 – Future of Healthcare,” part of the company’s Advanced Medical Technologies, that identifies 18 technologies that will impact healthcare paradigms by 2025.

January 16, 2017 — BioSig Technologies Inc. announced that the company’s Pure EP System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, was featured in the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now